143 related articles for article (PubMed ID: 23992305)
1. In silico and biochemical analyses identify quinone reductase 2 as a target of piceatannol.
Hsieh TC; Bennett DJ; Lee YS; Wu E; Wu JM
Curr Med Chem; 2013; 20(33):4195-202. PubMed ID: 23992305
[TBL] [Abstract][Full Text] [Related]
2. Antiproliferative effects of resveratrol and the mediating role of resveratrol targeting protein NQO2 in androgen receptor-positive, hormone-non-responsive CWR22Rv1 cells.
Hsieh TC
Anticancer Res; 2009 Aug; 29(8):3011-7. PubMed ID: 19661309
[TBL] [Abstract][Full Text] [Related]
3. Control of stability of cyclin D1 by quinone reductase 2 in CWR22Rv1 prostate cancer cells.
Hsieh TC; Yang CJ; Lin CY; Lee YS; Wu JM
Carcinogenesis; 2012 Mar; 33(3):670-7. PubMed ID: 22266466
[TBL] [Abstract][Full Text] [Related]
4. Biochemical and cellular evidence demonstrating AKT-1 as a binding partner for resveratrol targeting protein NQO2.
Hsieh TC; Lin CY; Bennett DJ; Wu E; Wu JM
PLoS One; 2014; 9(6):e101070. PubMed ID: 24968355
[TBL] [Abstract][Full Text] [Related]
5. Negative regulation of quinone reductase 2 by resveratrol in cultured vascular smooth muscle cells.
Cai JB; Zhang ZH; Xu DJ; Qian ZY; Wang ZR; Huang YZ; Zou JG; Cao KJ
Clin Exp Pharmacol Physiol; 2008 Dec; 35(12):1419-25. PubMed ID: 18671725
[TBL] [Abstract][Full Text] [Related]
6. In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2).
Nolan KA; Caraher MC; Humphries MP; Bettley HA; Bryce RA; Stratford IJ
Bioorg Med Chem Lett; 2010 Dec; 20(24):7331-6. PubMed ID: 21074425
[TBL] [Abstract][Full Text] [Related]
7. Piceatannol and resveratrol share inhibitory effects on hydrogen peroxide release, monoamine oxidase and lipogenic activities in adipose tissue, but differ in their antilipolytic properties.
Les F; Deleruyelle S; Cassagnes LE; Boutin JA; Balogh B; Arbones-Mainar JM; Biron S; Marceau P; Richard D; Nepveu F; Mauriège P; Carpéné C
Chem Biol Interact; 2016 Oct; 258():115-25. PubMed ID: 27475863
[TBL] [Abstract][Full Text] [Related]
8. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1.
Potter GA; Patterson LH; Wanogho E; Perry PJ; Butler PC; Ijaz T; Ruparelia KC; Lamb JH; Farmer PB; Stanley LA; Burke MD
Br J Cancer; 2002 Mar; 86(5):774-8. PubMed ID: 11875742
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of melanoma cell proliferation by resveratrol is correlated with upregulation of quinone reductase 2 and p53.
Hsieh TC; Wang Z; Hamby CV; Wu JM
Biochem Biophys Res Commun; 2005 Aug; 334(1):223-30. PubMed ID: 15993843
[TBL] [Abstract][Full Text] [Related]
10. 5-MCA-NAT does not act through NQO2 to reduce intraocular pressure in New-Zealand white rabbit.
Alarma-Estrany P; Crooke A; Pintor J
J Pineal Res; 2009 Sep; 47(2):201-209. PubMed ID: 19627460
[TBL] [Abstract][Full Text] [Related]
11. The two common polymorphic forms of human NRH-quinone oxidoreductase 2 (NQO2) have different biochemical properties.
Megarity CF; Gill JR; Caraher MC; Stratford IJ; Nolan KA; Timson DJ
FEBS Lett; 2014 May; 588(9):1666-72. PubMed ID: 24631540
[TBL] [Abstract][Full Text] [Related]
12. NRH:quinone oxidoreductase 2 (NQO2) and glutaminase (GLS) both play a role in large extracellular vesicles (LEV) formation in preclinical LNCaP-C4-2B prostate cancer model of progressive metastasis.
Dorai T; Shah A; Summers F; Mathew R; Huang J; Hsieh TC; Wu JM
Prostate; 2018 Nov; 78(15):1181-1195. PubMed ID: 30009389
[TBL] [Abstract][Full Text] [Related]
13. Mechanism-based inhibition of quinone reductase 2 (NQO2): selectivity for NQO2 over NQO1 and structural basis for flavoprotein inhibition.
Dufour M; Yan C; Siegel D; Colucci MA; Jenner M; Oldham NJ; Gomez J; Reigan P; Li Y; De Matteis CI; Ross D; Moody CJ
Chembiochem; 2011 May; 12(8):1203-8. PubMed ID: 21506232
[TBL] [Abstract][Full Text] [Related]
14. NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism.
Jamieson D; Wilson K; Pridgeon S; Margetts JP; Edmondson RJ; Leung HY; Knox R; Boddy AV
Clin Cancer Res; 2007 Mar; 13(5):1584-90. PubMed ID: 17332305
[TBL] [Abstract][Full Text] [Related]
15. In silico screening reveals structurally diverse, nanomolar inhibitors of NQO2 that are functionally active in cells and can modulate NF-κB signaling.
Nolan KA; Dunstan MS; Caraher MC; Scott KA; Leys D; Stratford IJ
Mol Cancer Ther; 2012 Jan; 11(1):194-203. PubMed ID: 22090421
[TBL] [Abstract][Full Text] [Related]
16. Three Australian Lepidosperma Labill. Species as sources of prenylated and oxyprenylated derivatives of piceatannol, resveratrol and pinosylvin: Melatoninergic binding and inhibition of quinone reductase 2.
Hamid K; Tran VH; Duke RK; Duke CC
Phytochemistry; 2022 Nov; 203():113396. PubMed ID: 35998831
[TBL] [Abstract][Full Text] [Related]
17. Quinone reductase 2 is an adventitious target of protein kinase CK2 inhibitors TBBz (TBI) and DMAT.
Leung KK; Shilton BH
Biochemistry; 2015 Jan; 54(1):47-59. PubMed ID: 25379648
[TBL] [Abstract][Full Text] [Related]
18. Evidence for NQO1 and NQO2 catalyzed reduction of ortho- and para-quinone methides.
Kucera HR; Livingstone M; Moscoso CG; Gaikwad NW
Free Radic Res; 2013 Dec; 47(12):1016-26. PubMed ID: 24074361
[TBL] [Abstract][Full Text] [Related]
19. Deficiency of NRH:quinone oxidoreductase 2 differentially regulates TNF signaling in keratinocytes: up-regulation of apoptosis correlates with down-regulation of cell survival kinases.
Ahn KS; Gong X; Sethi G; Chaturvedi MM; Jaiswal AK; Aggarwal BB
Cancer Res; 2007 Oct; 67(20):10004-11. PubMed ID: 17942934
[TBL] [Abstract][Full Text] [Related]
20. Biological activity of piceatannol: leaving the shadow of resveratrol.
Piotrowska H; Kucinska M; Murias M
Mutat Res; 2012; 750(1):60-82. PubMed ID: 22108298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
